New cancer clinical trial: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Published on: August 29, 2018 at 12:00PM
Conditions:   Breast Neoplasm Female;   Breast Cancer;   Breast Carcinoma;   Breast Tumor
Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Bicalutamide
Sponsors:   Providence Health & Services;   Bristol-Myers Squibb;   Memorial Sloan Kettering Cancer Center
Not yet recruiting
https://ift.tt/2wqFPlK